Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Journal stats
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Journal stats
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
N-glycosylation in the SERPIN domain of the C1-esterase inhibitor in hereditary angioedema
Zhen Ren, John Bao, Shuangxia Zhao, Nicola Pozzi, H. James Wedner, John P. Atkinson
Zhen Ren, John Bao, Shuangxia Zhao, Nicola Pozzi, H. James Wedner, John P. Atkinson
View: Text | PDF
Research Article Immunology

N-glycosylation in the SERPIN domain of the C1-esterase inhibitor in hereditary angioedema

  • Text
  • PDF
Abstract

Hereditary angioedema is an autosomal dominant disorder caused by defects in C1-esterase inhibitor (C1-INH), resulting in poorly controlled activation of the kallikrein-kinin system and bradykinin overproduction. C1-INH is a heavily glycosylated protein in the serine protease inhibitor (SERPIN) family, yet the role of these glycosylation sites remains unclear. To elucidate the functional impact of N-glycosylation in the SERPIN domain of C1-INH, we engineered 4 sets consisting of 26 variants at or near the N-linked sequon (NXS/T). Among these, 6 are reported in patients with hereditary angioedema and 5 are known C1-INH variants without accessible clinical histories. We systematically evaluated their expression, structure, and functional activity with C1s̄, FXIIa, and kallikrein. Our findings showed that of the 11 reported variants, 7 were deleterious. Deleting N at the 3 naturally occurring N-linked sequons (N238, N253, and N352) resulted in pathologic consequences. Altering these sites by substituting N with A disrupted N-linked sugar attachment, but preserved protein expression and function. Furthermore, an additional N-linked sugar generated at N272 impaired C1-INH function. These findings highlight the importance of N-linked sequons in modulating the expression and function of C1-INH. Insights gained from identifying the pathological consequences of N-glycan variants should assist in defining more tailored therapy.

Authors

Zhen Ren, John Bao, Shuangxia Zhao, Nicola Pozzi, H. James Wedner, John P. Atkinson

×

Figure 7

N272 glycosylation site variants.

Options: View larger image (or click on image) Download as PowerPoint
N272 glycosylation site variants.
(A) WB analysis of supernatants from t...
(A) WB analysis of supernatants from transfected WT and N272 variant constructs under reducing conditions. Recombinant expression of N271del (lane 3) and N272del (lane 5) was decreased. N271A, N272A, N272D, N271-N272del, K273del, and S275del (lanes 2, 4, 6, 7, 8, and 9) had normal secretion comparable to WT (lane 1). See Table 1. N272-linked glycan site has an atypical N-glycosylation consensus sequence, NNKIS, which is highlighted in blue, purple, orange, and red. (B) WB analysis of variants N272del and K273del before and after treatment with glycosidases. Before treatment, K273del (lane 3) had a slightly higher Mr compared with N272del (lane 2). After treatment, WB demonstrates that N272del (lane 5) and K273del (lane 6) had the same Mr. Human purified C1-INH was used as a positive control (lane 7, before treatment; lane 8, after treatment). Adopted from Ren et al. (6). Δ, post-degylcosylation. (C–F) Functional analysis of the N272 glycosylation site variants. (C and E) Absorbance is plotted against protein concentration. (D and F) Comparison of PKa and FXIIa binding between WT and N272 glycosylation site variants. The binding affinity of N271A, N272A, and N272D for PKa and FXIIa was comparable to WT, whereas N271del, N272del, K273del, and N271-N272del exhibited impaired binding activity to both substrates. Interestingly, S275del exhibited a markedly decreased binding to PKa, but not to FXIIa. Data represent mean ± SEM of 3 separate experiments. ***P < 0.001, ****P < 0.0001 by 1-way ANOVA with Dunnett’s multiple-comparison test. (G) Structural analysis of N272del and K273del. K273 is located in the loop immediately after hF. The deletion of K273 does affect the conformation of hF. K273del, previously reported, results in a new N-glycosylation site in C1-INH (37). The N271 residue is shown in pink, N272 in blue sphere, and K273 in purple.

Copyright © 2026 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts